Navigation Links
Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Date:1/7/2008

-First Combination Study of a MET and EGFR Inhibitor-

SOUTH SAN FRANCISCO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today announced that it has initiated a phase 1/2 trial of XL184 in patients with non-small cell lung cancer (NSCLC) who have had progressive disease while on a regimen containing erlotinib.

XL184 is a small molecule that simultaneously inhibits the MET, RET and VEGFR receptor tyrosine kinases. In the initial phase 1 part of the study, safety and pharmacokinetics of combining XL184 with erlotinib will be evaluated. The primary endpoint of the phase 2 part of the study is overall response rate. Secondary endpoints include progression-free survival, overall survival and pharmacodynamics.

"XL184 is a potent inhibitor of MET, and MET amplification has been shown to play an important role in the development of resistance to EGFR inhibitors in NSCLC," said Michael Morrissey, Ph.D., president of research and development of Exelixis. "Our preclinical data suggest that XL184 effectively inhibits growth of cancer cells that have become resistant to EGFR inhibitors through activation of the MET signaling pathway. XL184 also potently inhibits VEGFR, which is a validated target in the treatment of NSCLC. The compound has shown encouraging anti-tumor activity in an initial phase 1 trial and we are executing a phase 2 clinical development program, and are planning on initiation of a pivotal trial for XL184 in medullary thyroid cancer in 2008."

The phase 1/2 study of XL184 is expected to enroll up to 86 NSCLC patients who have had disease progression while on erlotinib. The phase 1 portion of the study will evaluate dose escalation of XL184 in combination with erlotinib, both
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
2. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
3. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
4. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
5. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
6. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
7. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
8. GlaxoSmithKline Accelerates Review of Exelixis XL880
9. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
10. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
11. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... 23, 2011 Reportlinker.com announces that ... available in its catalogue: ... Analysis of Water and Wastewater Management ... http://www.reportlinker.com/p0506839/Global-Water-Market-Outlook-Strategic-Analysis-of-Water-and-Wastewater-Management-in-the-Pharmaceutical-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Water_dis ...
... PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in Palos Verdes, CA.  Josef von Rickenbach, Chairman ... PAREXEL at 4:00 p.m.  PT on Wednesday, June 8, 2011. ... available through the "Investors" section of PAREXEL,s website ...
Cached Medicine Technology:Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 2Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 3Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 4PAREXEL International to Present at Goldman Sachs Healthcare Conference and Jefferies Global Healthcare Conference 2
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- The risk ... the holidays, so you need to be extra cautious, ... Day, we see a significant increase in patients coming ... at the Suffolk County Volunteer Firefighters Burn Center of ... celebrations should be full of joy, but if not ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 AngelWeddingDress.com tries ... to the online realm. Today, the business has introduced ... a site-wide prom dress promotion. , The new prom ... each and every dress lover. They are specially designed ... 2015 prom dresses should visit its website before ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part ... mobile applications on the iOS, Android, and Windows markets. Andrew ... the app review and shared with viewers how this is ... old saying goes, “A picture says a thousand words.” It’s ... a single image, because each picture holds a unique and ...
(Date:12/25/2014)... Newton, North Carolina (PRWEB) December 25, 2014 ... a North Carolina Retirement Community, recently showed their ... and girls of the Catawba County Parenting Network- ... meal, the 10 children gathered around the largest ... community to open presents purchased by residents of ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Retirement Community Residents Make Impact During Holiday Season 2
... ... ... ... WHITE PLAINS, N.Y. , March 22 Ford Motor Company President and Chief Executive Officer Alan Mulally is helping the March of Dimes give all babies a healthy ...
... Medicine (SHM) has announced that Steven Liu , MD, chairman and founder of healthcare IT company, Ingenious Med, is among the more than 150 hospitalists nationwide who have earned ... ... ... ...
... anticancer agent that preferentially kills tumor cells without apparent ... TRAIL, however, thus limiting its therapeutic potential. According to ... Journal of Cell Biology ( www.jcb.org ), ... cell differentiation protein) might represent a suitable means to ...
... GA While prevention methods appear to be helping ... antibiotic-resistant bacterium, a new superbug is on the rise, ... Network. New data shows infections from ... (MRSA) infections in community hospitals. "We found ...
... Discovery could provide target for future treatments, researchers say ... identified gene variations linked with an increased risk for ... The international research team analyzed DNA from more than ... had never smoked and found strong evidence that two ...
... ... Marketing Advisor has just surpassed the 10,000 subscriber milestone. , ... (PRWEB) March 22, 2010 -- According to ... has just surpassed over 10,000 subscribers., , ,Written and published exclusively by medical ...
Cached Medicine News:Health News:Ford CEO Asks Nation to March to Prevent Preterm Birth 2Health News:Ford CEO Asks Nation to March to Prevent Preterm Birth 3Health News:Ingenious Med Founder, Steven Liu, Earns Senior Fellow in Hospital Medicine Designation 2Health News:Ingenious Med Founder, Steven Liu, Earns Senior Fellow in Hospital Medicine Designation 3Health News:Ingenious Med Founder, Steven Liu, Earns Senior Fellow in Hospital Medicine Designation 4Health News:New superbug surpasses MRSA infection rates in community hospitals 2Health News:Medical Marketing Newsletter Reaches 10,000 Subscribers 2
... titanium alloy implants used for ... They are indicated where high ... SuperAnchor uses four Nitinol arcs ... small size. The unique design ...
... Super Revo Suture Anchor offers a simple ... mini-open rotator cuff repair. The cutting tip ... pre-threaded with two #2 strands of braided ... management are avoided with the Independent Suture ...
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
... Revo Suture Anchor offers a simple and ... rotator cuff repair. The cutting tip requires ... with two #2 strands of braided polyester ... are avoided with the Independent Suture Sliding ...
Medicine Products: